

- Pharmacol Res. 2023 Jan 18;188:106668.
- Antimicrob Agents Chemother. 2023 Feb 28;e0148722.
- Research Square Preprint. 2020 Dec.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Wang X, et al. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. *Cancer Res.* 2013 Nov 1;73(21):6516-25.
- [2]. Byers LA, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clin Cancer Res.* 2013 Jan 1;19(1):279-90.
- [3]. Chenjing Zhu, et al. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. *Mol Cancer.* 2019 Nov 4;18(1):153.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA